Published in J Transl Med on August 07, 2006
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res (2010) 1.26
Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis (2014) 0.97
Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. World J Gastroenterol (2008) 0.96
Association between hypermethylation of DNA repetitive elements in white blood cell DNA and early-onset colorectal cancer. Epigenetics (2013) 0.94
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle (2012) 0.89
Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag Res (2011) 0.85
ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells. Oncotarget (2016) 0.81
DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PLoS One (2012) 0.80
A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers. Transl Oncol (2014) 0.79
Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. J Med Case Rep (2011) 0.79
Dual regulation of P-glycoprotein expression by trichostatin A in cancer cell lines. BMC Mol Biol (2012) 0.78
Promoter demethylation of nuclear factor-erythroid 2-related factor 2 gene in drug-resistant colon cancer cells. Oncol Lett (2015) 0.75
Hepatitis viruses exploitation of host DNA methyltransferases functions. Clin Exp Med (2015) 0.75
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell (1997) 6.45
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet (2000) 5.72
The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res (1999) 4.74
Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev (1993) 3.64
DNA methylation, methyltransferases, and cancer. Oncogene (2001) 3.30
Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood (2001) 3.07
Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res (2003) 2.37
Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells. Nucleic Acids Res (1998) 2.17
Deciphering cellular states of innate tumor drug responses. Genome Biol (2006) 1.83
A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun (1999) 1.77
De novo CpG island methylation in human cancer cells. Cancer Res (2006) 1.73
Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum (2003) 1.56
Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol (2002) 1.46
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res (2003) 1.30
New science-based endpoints to accelerate oncology drug development. Eur J Cancer (2005) 1.16
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res (1997) 1.16
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int (2006) 1.15
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer (2005) 1.14
Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res (1997) 1.13
Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood (1998) 1.12
Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res (1989) 1.08
Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms. J Biol Chem (1999) 0.99
Hydralazine target: from blood vessels to the epigenome. J Transl Med (2006) 0.98
MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res (2000) 0.98
Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. Int Rev Immunol (2004) 0.94
Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res (1988) 0.92
Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia (2000) 0.92
Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev (2005) 0.92
Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem (1999) 0.90
Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis (2005) 0.90
Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem Pharmacol (1991) 0.88
5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis (2001) 0.87
Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer (2006) 0.83
Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells. Oncology (2004) 0.83
Demethylation of the human MDR1 5' region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet (1997) 0.83
Determination of 5-methyl-cytosine and cytosine in tumor DNA of cancer patients. Electrophoresis (2005) 0.82
Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. Leukemia (1999) 0.82
Differential expression of DNA-methyltransferases in drug resistant murine neuroblastoma cells. Cancer Detect Prev (2002) 0.81
[The expression of DNA methyltransferase DNMT1, 3A and 3B in acute leukemia and myelodysplastic syndrome]. Zhonghua Nei Ke Za Zhi (2003) 0.77
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev (2008) 1.74
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One (2006) 1.48
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res (2003) 1.30
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer (2005) 1.24
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer (2005) 1.14
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol (2010) 1.05
Hydralazine target: from blood vessels to the epigenome. J Transl Med (2006) 0.98
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med (2006) 0.91
Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep (2010) 0.85
Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int (2006) 0.85
DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PLoS One (2012) 0.80
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk (2012) 0.80
Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. Anticancer Drugs (2005) 0.79
Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response. BMC Cancer (2006) 0.79
Bone marrow as a site for pancreatic islet transplantation. Blood (2010) 0.76
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol (2014) 0.75
The reduction of Calpain-10 expression is associated with risk polymorphisms in obese children. Gene (2012) 0.75
Specific patterns of DNA copy number gains and losses in eight new glioblastoma multiforme cell lines. Int J Oncol (2003) 0.75
Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. Med Oncol (2010) 0.75